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Abstract
 
Aims
 
Krüppel-like factor 11 (
 
KLF11
 
) is a transcriptional factor of the zinc finger domain family that regulates the
expression of insulin. In North European populations, its common functional variant Q62R (rs35927125) is a strong
genetic factor for Type 2 diabetes (
 
P
 
 
 
=
 
 0.00033, odds ratio for G allele 
 
=
 
 1.29, 95% CI 1.12–1.49). We examined the con-
tribution of 
 
KLF11
 
 variants to the susceptibility to Type 2 diabetes in a Japanese population.
 
Methods
 
By re-sequencing Japanese individuals (
 
n
 
 
 
=
 
 24, partly 96), we screened all four exons, exon/intron boundaries
and flanking regions of 
 
KLF11
 
. Verified single nucleotide polymorphisms (SNPs) were genotyped in 731 initial samples
(369 control and 362 case subjects). Subsequently, we tested for association in 1087 samples (524 control and 563 case
subjects), which were collected in different districts of Japan from the initial samples.
 
Results
 
We identified eight variants, including a novel A/C variant on intron 3, but no mis-sense mutations. In an asso-
ciation study, we failed to find any significant result of SNPs (minor allele frequency 8.2–46.2%) after correcting for
multiple testing. Similarly, no haplotypes were associated with Type  2 diabetes. It is notable that the G allele in
rs35927125 was completely absent in 1818 Japanese individuals.
 
Conclusions
 
Genetic variants in 
 
KLF11
 
 are unlikely to have a major effect of Type 2 diabetes in the Japanese population,
although they were significantly associated in North European populations. These observations might help to determine
the role of 
 
KLF11
 
 variants in Type 2 diabetes in different populations.
Diabet. Med. 25, 19–26 (2008)
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Introduction
 
The Krüppel-like factor (KLF) family is characterized by the
presence of three highly homologous Cys2/His2 type zinc
finger domains near the C-terminal region. It is a transcription
factor involved in cellular development and differentiation.
To date, 17 members of the KLF family have been identified,
and each could play an important role in mammalian cells [1,2].
 
KLF2
 
 is a negative regulator of adipocyte differentiation [3],
and 
 
KLF5
 
 regulates the differentiation of smooth muscle and
adipose tissue [4].
Recently, it has been shown that 
 
KLF11
 
, inducible by trans-
forming growth factor (TGF)-
 
β
 
, regulates exocrine cell growth
and behaves as a tumour suppressor in pancreatic cancer [5].
Molecular mechanistic studies in pancreatic B-cells showed
that the 
 
KLF11
 
 gene is a glucose-induced regulator of the insulin
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gene. Various homozygous and heterozygous variants, including
deletion, insertion and mis-sense mutations, have been detected
within this gene, and its common functional variant Q62R
(rs35927125) is significantly associated with Type 2 diabetes
in North European populations [6]. This raises the possibility
that 
 
KLF11
 
 is one of the key genes for predisposition to diabetes
that affects insulin secretion.
The disease susceptibility variants modestly affect the risk of
Type 2 diabetes, and a large study population is required to
ensure substantial significance. So far, robust reproducible
associations have been documented in a few genes, such as the
P12A polymorphism in peroxisome proliferator-activated
receptor 
 
γ
 
 (encoded by 
 
PPAR
 
γ
 
) [7], the E23K polymorphism in
 
KCNJ11
 
, which encodes the ATP-sensitive K
 
+
 
 channel Kir6.2
[8], and common variants in the transcription factor 7-like 2
(
 
TCF7L2
 
) gene [9].
In contrast, some association studies have given conflicting
results, with initial findings not confirmed in all subsequent
studies. More recently, a study of 8676 Caucasian individuals
failed to replicate the association between 
 
KLF11
 
 variants and
Type 2 diabetes [10], despite an association in North Euro-
pean populations [6]. To analyse the substantial effect of
genetic variants, it is necessary to have independent reproduc-
ible analysis in multiple ethnic groups.
In the light of the potential role of 
 
KLF11
 
 in insulin action,
we present a detailed re-examination of the 
 
KLF11
 
 variants
and test the possible association with Type 2 diabetes in 1818
Japanese participants.
 
Patients and methods
 
The World Health Organization criteria were used for the
classification of Type 2 diabetic patients and healthy control
subjects [11]. Type 2 diabetes was clinically defined as a gradual
onset of the disease in adulthood, requiring medication. Patients
with mitochondrial diseases or maturity-onset diabetes of the
young (MODY) were excluded. Using birthplace information,
all subjects were of full Japanese ancestry. A description of
cases and control subjects is provided in Table 1.
We prepared two independent samples of 1818 Japanese
individuals (925 cases and 893 control subjects). In 731 initial
samples, 362 Type 2 diabetic patients and 369 healthy control
subjects were recruited from the outpatient clinic of Tokushima
University Hospital. They are all residents of Shikoku Island,
one of the four main islands of Japan.
Even within relatively homogenous genetic isolates, such as
Icelanders, there is a substantial divergence in allele frequencies
among geographical areas [12]. To prevent the substantial di-
vergence in allele frequencies from population stratification, we
replicated the association in the other unrelated 1087 samples
of 563 cases and 524 control subjects. In the replication test,
cases were collected from Kyoto Prefectural University Hospi-
tal and its related hospitals. They are all residents of the Kansai
district located in the western part of the main island of Japan,
130 miles away from Shikoku Island, by sea. Non-diabetic
control subjects were recruited from the general population.
A large number of control subjects (96.7%) was recruited
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through the Pharma SNP consortium (PSC) in Japan (http://
www.jpma.or.jp/psc/frame-e.html). Through the consortium,
their health and absence of diabetes were intensively checked.
The study protocol was approved by the Institutional Review
Board of the University of Tokushima. Written informed consent
was obtained from all participants prior to blood sampling.
 
Sequencing of the 
 
KLF11
 
 gene
 
To analyse the variants as previously reported and search for
new ones, we screened all four exons, including exon/intron
boundaries, 5
 
′
 
-untranslated region (UTR), 3
 
′
 
-UTR and 1000 bp
upstream and downstream of 
 
KLF11
 
 with 24 randomly selected
samples (12 control subjects and 12 cases). We partly used 96
additional case samples to confirm the variants.
The 
 
KLF11
 
 gene consists of four exons that span 11 kb of
genomic DNA on chromosome 2p25. The total length of the
re-sequencing region was about 8 kb. Coding regions and exon/
intron boundaries were divided into 15 overlapping fragments
and amplified by PCR. PCR primers were designed by Primer3
program (http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_
www.cgi) on the basis of the genomic contig sequence (gene ID:
8462, AC104794 and NM_003597). Details of the primers
sequences are available on request.
PCR fragments were sequenced in both directions using the
ABI BigDye Terminator chemistry method on an ABI 3100 or
3730xl automated sequencer (Applied Biosystems, Foster City,
CA, USA). The sequencing conditions followed the protocol
recommended by the manufacturer. The results were integrated
using a SeqScape version 2.1.1 (Applied Biosystems), and indi-
vidual single nucleotide polymorphisms (SNPs) were manually
checked by two experienced researchers. Ambiguous base iden-
tifications were sequenced again, and SNPs were identified
based on the sequence reported in GenBank.
 
SNPs genotyping
 
Variants identified by either sequencing or databases were
genotyped using the TaqMan Allelic Discrimination Assay
(Applied BioSystems) on an ABI Prism 7700 (Applied BioSystems).
Thermal cycling conditions followed the manufacturer’s instruc-
tions. In our laboratory, genotyping showed 100% concordance
with sequencing as previously described [13,14].
 
Statistical analysis
 
The statistical power was calculated using a PS power and sample-
size program (http://biostat.mc.vanderbilt.edu/twiki/bin/view/
Main/PowerSampleSize) and Genetic power calculator (http://
pngu.mgh.harvard.edu/~purcell/gpc/). With a minor allele fre-
quency (MAF) of 0.4, our sample size had 60–80% power to
detect the SNPs with an odds ratio of 1.2–1.5 at a significance
level of 0.05. With less frequent SNPs (assuming a MAF of 0.2),
the same sample size showed lower power (57.4%) at the same
significance level.
To test the association with Type 2 diabetes, four types of
 
χ
 
2
 
-test (allele, genotype, dominant and recessive model) were
calculated with SNPAlyze version 5.1 software (Dynacom, Yoko-
hama, Japan). The crude odds ratio (OR) and 95% confidence
interval (CI) were also calculated. To determine the significance
level of the tests, nominal 
 
P
 
 values were corrected using Bonfer-
roni’s correction to avoid false-positive results. We corrected
for 48 tests the total number of hypotheses (e.g. 11 SNPs
multiplied by four models plus four haplotypes). We also used
permutation testing as the correction for multiple testing
(http://www.broad.mit.edu/mpg/haploview/). Distribution of a
test statistic was estimated by analysing the statistics for a
random sampling of 10 000 iterated permutations with a fixed
total number of both cases and control subjects [15]. Devi-
ations from Hardy–Weinberg equilibrium were examined using
the 
 
χ
 
2
 
-test (SNPAlyze version 5.1), and results of 
 
P
 
 
 
<
 
 0.05 in
control subjects were excluded from the analysis.
 
Estimation of linkage disequilibrium (LD) and haplotype 
frequency
 
Simple pairwise LD coefficients, |D
 
′
 
| and 
 
r
 
2
 
, were calculated
with SNPAlyze version 5.1 (Dynacom). This analysis was
under the assumption of Hardy–Weinberg equilibrium. Haplo-
types were inferred by the expectation–maximization (EM) al-
gorithm. The differences of haplotype frequencies were
calculated with 
 
χ
 
2
 
-tests and permutation tests. Distribution of
a test statistic was estimated by analysing the statistics for a ran-
dom sampling of 10 000 iterated permutations with a fixed to-
tal number of both cases and control subjects [15].
 
Results
 
Screening of the 
 
KLF11
 
 gene variants in Japanese populations
 
Based on the first report [6], we screened the genetic variants,
including four major variants, Q62R in exon 2 (rs35927125),
T220M in exon 3 (rs34336420), A347S in exon 3 (no dbSNP
ID) and V395V in exon 3 (rs11687357). T220M and A347S
are rare variants found only in MODY-like or early onset
diabetes families. Q62R shows a MAF of 0.115 in their nor-
moglycaemic group.
The results are shown in Table 2. With the re-sequencing
effort, a total of eight variants were identified in 24 Japanese
samples. These variants are believed to be common SNPs,
showing a MAF of over 0.10 (0.104–0.354). Of eight variants,
a novel A/C variant was detected in intron 3 without the
register in the public database. Notably, there was no G allele
of rs35927125 in the initial 24 samples and additional 96
case samples, although this mis-sense variant was strongly
associated with Type 2 diabetes in the first report. In addition,
we failed to detect two mis-sense variants (T220M and A347S)
in 120 samples. There was no insertion or deletion. Within three
zinc finger domains of the 
 
KLF11
 
 gene, we found no variants.
 
Association study with the genetic variants in 
 
KLF11
 
As a result of screening, nine TaqMan probes were designed
within the coding region of 
 
KLF11
 
, in which Q62R (rs35927125)
was included to examine its genotypes in more samples. To
estimate LD around the 
 
KLF11
 
 gene, we placed three additional 
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Table 2
 
Re-examination of the 
 
KLF11
 
 gene variants
Genome 
position
Variants previously 
reported (allele 1/2) Location dbSNP ID
Amino acid 
change
First 24 samples (12 controls and 12 cases) Additional 96 samples (96 cases)
Allele 1 Hetero Allele 2
Allele 2 
frequency Allele 1 Hetero Allele 2
Allele 2 
frequency
10 132 783 G/C 5
 
′
 
-flanking No No 24 0 0 0 95 0 0 0
10 132 891 Insertion (ACTTA) 5
 
′
 
-flanking No No 24 0 0 0 — — — —
 
10 133 094 G/A
 
5
 
′
 
-flanking rs4669520 No 18 5 1 0.146 65 29 2 0.172
10 133 162 Insertion (CT) 5
 
′
 
-flanking No No 24 0 0 0 96 0 0 0
10 133 418 Insertion (G) 5
 
′
 
-flanking rs35035311 No 24 0 0 0 — — — —
10 133 452 T/A 5
 
′
 
-flanking No No 24 0 0 0 — — —
 
−
 
10 134 357 Deletion (GCC) 5
 
′
 
-UTR No No 24 0 0 0 96 0 0 0
10 135 282 C/T Intron 1 No No 24 0 0 0 — — — —
10 137 017 A/G Exon 2 rs35927125 Q62R 24 0 0 0 96 0 0 0
10 138 131 G/C Intron 2 No No 24 0 0 0 — — — —
10 138 721 C/T Exon 3 rs34336420 T220M 24 0 0 0 96 0 0 0
10 139 101 G/T Exon 3 No A347S 24 0 0 0 96 0 0 0
 
10 139 247 T/A
 
Exon 3 rs11687357 V395V 18 5 1 0.146 65 27 2 0.165
 
10 140 297 C/T
 
Intron 3 rs6432052 No 18 5 1 0.146 67 27 2 0.161
 
10 140 433 T/C
 
Intron 3 rs6432053 No 11 9 4 0.354 53 35 8 0.266
 
10 140 523 A/C*
 
Intron 3 No No 19 5 0 0.104 79 17 0 0.088
10 140 652 C/T Intron 3 No No 24 0 0 0 96 0 0 0
 
10 140 713 G/A
 
Intron 3 rs6721191 No 18 5 1 0.146 67 27 2 0.161
10 140 721 Deletion (A) Intron 3 No No 24 0 0 0 96 0 0 0
10 143 776 C/A 3
 
′
 
-UTR rs4444493 No 24 0 0 0 — — — —
 
10 144 790 C/T
 
3′-UTR rs4669522 No 17 5 1 0.152 — — — —
10 145 085 C/T 3′-UTR rs7632 No 11 9 4 0.354 — — — —
Genome position is based on the NCBI build 35. The eight variants identified in Japanese individuals, genome positions and variant types are shown in bold face.
*Novel A/C variant in intron 3 was detected in this study.
KLF11, Krüppel-like factor 11; NCBI, National Center for Biotechnology Information; UTR, untranslated region.Original article DIABETICMedicine
© 2008 The Authors.
Journal compilation © 2008 Diabetes UK. Diabetic Medicine, 25, 19–26 23
TaqMan probes (rs4073397, rs3885668 and rs10171924)
outside the coding region with the HapMap JPT database as a
reference (http://www.hapmap.org). These SNPs covered the
region of interest with, on average, a less than 10-kb interval.
All together, 12 TaqMan probes were designed for genotyp-
ing. After removing rs6432052, which failed to be successfully
genotyped using the TaqMan method, the remaining 11
variants, including rs35927125, were genotyped in 1818
samples. The concordance rate of duplicate genotypes was over
99%. The genotyping success rate was between 98.5–100%.
The results of genotyping and association with Type 2
diabetes are shown in Table 3. The genotype distribution was
in the Hardy–Weinberg equilibrium (P > 0.05). In all 1818
samples, there was no G allele in rs35927125. No SNPs across
the coding region of the KLF11 gene showed a significant
association in the initial 731 samples (from the Tokushima
district). This result was replicated in larger cohorts with 524
control subjects (from PSC) and 563 Type 2 diabetic patients
(from the Kansai district). In a joint analysis of all samples,
no significant association of diabetes was observed with any
SNPs, including a novel A/C variant in intron 3. This SNP was
not studied in either the first [6] or the second report of
Caucasian [10]. In two Japanese controls, there was no signific-
ant difference in allele frequencies, suggesting no harmful
biases in the two control groups (Supplementary Table 1).
With rs4073397 located 21 kb upstream from a start codon,
the nominal P value showed a weak association (P = 0.010,
allele model). However, this value was not significant after
adjustment with Bonferroni’s correction (corrected for 48 tests),
although a marginal association was observed with permuta-
tion testing (permutation P = 0.046). When the analysis was
separated by initial and replication tests, neither showed
significant results (P = 0.086 and 0.058, allele model) (Supple-
mentary Tables 2 and 3).
In this study, case–control samples were not completely
matched for age. To examine whether this bias affected the
analysis, 446 control samples under the age of 35 years were
excluded. The genotyping data were reanalysed with 447
control subjects over the age of 35 years and 925 cases. Once
again, none of the SNPs was significant (P > 0.05),  but
rs4073397 showed nominal association with Type 2 diabetes
(P = 0.004, allele model). This value was not significant after
adjustment for multiple testing, but it should be noted that this
sample size had considerably reduced power (41.6%).
As a result, statistical significance, assessed using a correc-
tion for multiple testing, showed no association with Type 2
diabetes, except for rs4073397 with a marginal association.
LD estimation and haplotype-based association study
As shown in Fig. 1, simple pairwise LD values, quantified by
|D′| and r2, were calculated in 893 control subjects. With the
definition of |D′|, single strong LD values (|D′| > 0.9)  were
found within nine SNPs (from rs3885668 to rs10171924)
across the KLF11 gene. In contrast, two haplotype blocks were
found: one including rs3885668, rs4669520 and rs11687357
and the other rs6721191 and rs4669522, with r2 values > 0.9.
The total frequency of all haplotypes was over 98%.
FIGURE 1 Genomic structure of KLF11 and pairwise LD values with 10 verified SNPs across the KLF11 gene. In the upper part, the KLF11 gene 
structure and the positions of 10 SNPs are indicated based on the NCBI human build 35. Exons are shown as boxes. Coding sequences are represented 
as white boxes, and untranslated regions as grey boxes. Introns and flanking sequences are shown as lines connecting the boxes. Two major variants 
(Q62R and V395V), start (ATG) and stop (TGA) codons are indicated as arrows. In the lower part, simple pairwise LD values, |D′| (right) and r2 (left), 
were calculated with the SNPAlyze version 5.1 (Dynacom) using 893 control samples. Blue and red columns indicate the values over 0.9 with |D′| and 
r2. KLF11, Krüppel-like factor 11; LD, linkage disequilibrium; NCBI, National Center for Biotechnology Information; SNP, single nucleotide 
polymorphism.D
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Table 3 Genotype and allele frequencies for 11 SNPs in 1818 Japanese individuals
Genome 
position
Variants 
Allele 1/2 Location dbSNP ID
Information 
of HapMap 
JPT
Amino 
acid 
change
Genotype frequency
P value*
Minor allele 
frequency
P value**
Permutation 
P value
Odds 
ratio 95% CI
Hardy-Weinberg
equilibrium test
Genotype
Control 
(n = 893)
Case 
(n = 925)
Control 
(n = 893)
Case 
(n = 925) P value
10 112 635 G/A 5′-flanking rs4073397 Available No GG 259 (0.29) 216 (0.23) 0.021 0.462 0.504 0.010 0.046 1.186 1.04–1.35 0.90
GA 439 (0.49) 479 (0.52)
AA 191 (0.21) 224 (0.24)
10 129 077 T/C 5′-flanking rs3885668 Available No TT 636 (0.71) 640 (0.70) 0.468 0.156 0.170 0.283 0.710 1.101 0.93–1.32 0.86
TC 233 (0.26) 248 (0.27)
CC 23 (0.03) 32 (0.03)
10 133 094 G/A 5′-flanking rs4669520 No No GG 636 (0.71) 636 (0.69) 0.571 0.157 0.170 0.291 0.719 1.100 0.92–1.32 0.70
GA 232 (0.26) 252 (0.27)
AA 24 (0.03) 30 (0.03)
10 137 017 A/G Exon 2 +143 rs35927125 No Q62R AA 893 (1.00) 925 (1.00) — — — — −—— — —
AG 0 0
GG 0 0
10 139 247 T/A Exon 3 +873 rs11687357 No V395V TT 635 (0.72) 633 (0.70) 0.518 0.152 0.166 0.272 0.687 1.106 0.92–1.33 0.77
TA 224 (0.25) 241 (0.27)
AA 22 (0.02) 29 (0.03)
10 140 433 T/C Intron 3 +1113 rs6432053 Available No TT 442 (0.50) 457 (0.50) 0.880 0.292 0.296 0.758 0.998 1.023 0.89–1.18 0.78
TC 370 (0.42) 381 (0.41)
CC 73 (0.08) 82 (0.09)
10 140 523 A/C Intron 3 +1203 no No No AA 749 (0.84) 765 (0.83) 0.331 0.082 0.091 0.331 0.775 1.122 0.89–1.41 0.83
AC 136 (0.15) 146 (0.16)
CC 5 (0.01) 11 (0.01)
10 140 713 G/A Intron 3 +1393 rs6721191 No No GG 638 (0.72) 643 (0.70) 0.522 0.154 0.167 0.269 0.680 1.105 0.93–1.32 0.89
GA 229 (0.26) 250 (0.27)
AA 22 (0.02) 29 (0.03)
10 144 790 C/T 3′-UTR +1558 rs4669522 Available No CC 640 (0.72) 643 (0.70) 0.463 0.154 0.168 0.241 0.637 1.112 0.93–1.33 0.93
CT 231 (0.26) 251 (0.27)
TT 22 (0.02) 30 (0.03)
10 145 085 C/T 3′-UTR +1853 rs7632 Available No CC 443 (0.50) 454 (0.50) 0.768 0.290 0.296 0.671 0.990 1.032 0.89–1.19 0.78
CT 368 (0.42) 374 (0.41)
TT 72 (0.08) 83 (0.09)
10 152 112 G/A 3′-flanking rs10171924 Available No GG 634 (0.71) 640 (0.70) 0.483 0.156 0.166 0.399 0.850 1.080 0.90–1.29 0.99
GA 235 (0.26) 243 (0.27)
AA 21 (0.02) 30 (0.03)
Genome position is based on the NCBI build 35.
P values for *genotype frequency and **allele frequency. Permutation P value are calculated for allele frequency.
Hardy–Weinberg equilibrium is calculated using only control subjects.
The total of genotype frequencies does not reach 1.0 because undetermined results were excluded from this table.
CI, confidence interval; NCBI, National Center for Biotechnology Information; SNP, single nucleotide polymorphism.Original article DIABETICMedicine
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In the analysis of |D′|, we found no haplotype-based associ-
ation with Type 2 diabetes in either the initial (Tokushima
district) or replication samples (Kansai district). In the joint
analysis of all samples, the result was also non-significant
(Table 4). Additionally, there was no significant association of
different haplotypes with the definition of r2 (data not shown).
Discussion
As the KLF11 gene is one of the key regulators in insulin secre-
tion, we considered KLF11 to be an important candidate gene
for Type 2 diabetes and systematically surveyed the genetic
variants. Although common alleles with an OR of 1.2–1.5
could be detected with 60–80% power with prior simulation,
we could not find any strong evidence with single–SNPs asso-
ciation tests and haplotype analyses in 1818 Japanese subjects.
However, the effect of less frequent SNPs might be underesti-
mated, as our power to detect less frequent SNPs was much
less. It is therefore important to conduct a meta-analysis
and/or larger clinical trial to detect the modest effect of less
frequent variants in this gene [16,17].
When identifying the disease-susceptibility variants, type 1
error (false positive) is of particular importance, and needs to
be minimized by statistical methods [18]. We used Bonferroni’s
correction to adjust the significance level in disease association.
We also used the permutation method to control for a type 1
error. Even after these two analyses, our data do not provide
strong evidence that the KLF11 variant is associated with
Type 2 diabetes in our Japanese population.
Nevertheless, there might be a marginal association with
rs4073397 located 21 kb upstream from the coding region and
outside the LD block defined by |D′|. With the hepatocyte
nuclear factor 4α (HNF4α) gene, the pancreas-specific tran-
scription start site is located 45 kb upstream relative to that of
the liver form, and SNPs within the distal promoter region
showed significant association with Type 2 diabetes [19,20].
We could not completely exclude the possibility of weak genetic
contributions in the putative regulatory region of the KLF11
gene, but the actual mechanism of how the variant would
affect the regulation of KLF11 remains to be elucidated.
Although the contribution of genetic factors to the risk of
Type 2 diabetes was extensively examined, it remains unclear
how the discrepancy arose in studies that analysed the disease-
susceptibility variants [21]. In the first report, the G allele in
rs35927125 showed the significant association, but this risk
allele was completely absent in Japanese individuals. In
addition, a recent large study failed to find an association of
the Q62R-allele in an independent Caucasian cohort [10].
In previous association studies [22–24], a similar case showed
that the frequency of K121Q variant in ectoenzyme nucleotide
pyrophosphate phosphodiesterase 1 (ENPP1) was quite dif-
ferent among the ethnic groups. It is possible that the disease-
susceptibility induced by variants is modulated by complicated
parameters, such as other ethnic specific genetic and/or envi-
ronmental factors [25].
In conclusion, we were unable to find any association of
common KLF11 variants with Type 2 diabetes in 1818
Japanese subjects, although a larger study may be required
to completely exclude the potential effect of rare variants
on this gene. The present association study contributes to
the future conclusive results of KLF11 variants in different
populations.
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Table 4 Haplotype analyses with nine SNPs defined by |D′|
Haplotypes
SNPs
123456789
Number of haplotypes and frequencies
P value
Permutation 
P value Control (frequency) Case (frequency) Overall (frequency)
1 TGTTAGCCG 1256 (0.703) 1294 (0.699) 2550 (0.701) 0.803 0.825
2 TGTCAGCTG 238 (0.133) 230 (0.124) 468 (0.129) 0.421 0.430
3 CAACCATTA 143 (0.080) 168 (0.091) 311 (0.086) 0.247 0.265
4 CAACAATTA 126 (0.071) 132 (0.071) 258 (0.071) 0.925 0.951
Total  (> 0.99)  (> 0.99)  (> 0.99)
SNP 1 is equivalent to rs3885668 (T/C), SNP 2 to rs4669520 (G/A), SNP 3 to rs11687357 (T/A), SNP 4 to rs6432053 (T/C), SNP 5 to intron 
3 +1203 (A/C), SNP 6 to rs6721191 (G/A), SNP 7 to rs4669522 (C/T), SNP 8 to rs7632 (C/T) and SNP 9 to rs10171924 (G/A).
The total frequencies of haplotypes do not reach 1.0 because rare haplotypes with frequencies under 0.05 are excluded.
P values are calculated by χ2-tests between case and control subjects with the permutation method.
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